Design Therapeutics (DSGN) EBITDA (2020 - 2026)

Design Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$19.7 million for Q1 2026.

• In Q1 2026, EBITDA fell 11.08% year-over-year to -$19.7 million; the TTM figure through Mar 2026 stood at -$78.8 million (down 35.35% YoY), while the FY2025 annual figure was -$79.5 million, down 27.39% from the prior year.
• EBITDA came in at -$19.7 million for Q1 2026 at Design Therapeutics, down from -$18.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$10.5 million in Q4 2023 to a low of -$21.6 million in Q2 2025.
• A 5-year average of -$16.4 million and a median of -$16.8 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 153.05% in 2022 and jumped 40.65% in 2024, its largest moves.
• Design Therapeutics' EBITDA stood at -$16.8 million in 2022, then jumped by 37.65% to -$10.5 million in 2023, then slumped by 59.04% to -$16.7 million in 2024, then fell by 8.84% to -$18.2 million in 2025, then fell by 8.46% to -$19.7 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$19.7 million, -$18.2 million, and -$19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison